Avalo Therapeutics (NASDAQ:AVTX) Issues Quarterly Earnings Results, Misses Expectations By $0.27 EPS

Avalo Therapeutics (NASDAQ:AVTX) issued its quarterly earnings data on Thursday. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.27), FiscalAI reports.

Avalo Therapeutics Stock Down 0.7%

Shares of NASDAQ:AVTX traded down $0.14 on Thursday, hitting $18.70. 596,212 shares of the company traded hands, compared to its average volume of 1,200,460. The stock has a 50 day simple moving average of $17.22 and a 200-day simple moving average of $16.27. The company has a market cap of $989.29 million, a PE ratio of -3.42 and a beta of 0.80. Avalo Therapeutics has a 52 week low of $8.01 and a 52 week high of $24.27.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Mizuho boosted their price target on shares of Avalo Therapeutics from $39.00 to $45.00 and gave the company an “outperform” rating in a research report on Thursday, May 14th. Wedbush reduced their price target on Avalo Therapeutics from $40.00 to $34.00 and set an “outperform” rating on the stock in a research note on Thursday, May 14th. Wolfe Research started coverage on Avalo Therapeutics in a report on Thursday, April 9th. They issued an “outperform” rating and a $48.00 price objective for the company. Citizens Jmp dropped their target price on shares of Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating on the stock in a report on Thursday, May 14th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Avalo Therapeutics in a research report on Friday, July 24th. Thirteen analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Avalo Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $45.80.

Insider Buying and Selling

In other Avalo Therapeutics news, insider Mittie Doyle sold 1,450 shares of the firm’s stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $18.00, for a total transaction of $26,100.00. Following the completion of the sale, the insider directly owned 51,776 shares in the company, valued at approximately $931,968. This trade represents a 2.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 4.46% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Boothbay Fund Management LLC purchased a new position in Avalo Therapeutics in the 2nd quarter worth about $56,000. Dimensional Fund Advisors LP purchased a new stake in Avalo Therapeutics in the third quarter worth approximately $143,000. Jump Financial LLC bought a new stake in Avalo Therapeutics in the 4th quarter worth approximately $238,000. Persistent Asset Partners Ltd bought a new position in shares of Avalo Therapeutics during the 4th quarter valued at $274,000. Finally, Hudson Bay Capital Management LP purchased a new position in shares of Avalo Therapeutics in the 4th quarter worth $305,000. 87.06% of the stock is owned by institutional investors.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.